Some cancer patients on chimeric antigen receptor (CAR) T-cell therapy, a novel cancer treatment considered a breakthrough in the past decade, developed T lymphoma as an additional cancer—a very rare phenomenon.
As of Dec. 6, 11 cases of T-cell lymphomas have been reported to the U.S. Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) Public Dashboard. The FDA is investigating the link.
